Zobrazeno 1 - 10
of 170
pro vyhledávání: '"Francesco, Franchi"'
Autor:
Larisa H. Cavallari, Craig R. Lee, Francesco Franchi, Ellen C. Keeley, Joseph S. Rossi, Cameron D. Thomas, Yan Gong, Caitrin W. McDonough, Petr Starostik, Maryam J. Al Saeed, Latonya Been, Natasha Kulick, Jean Malave, Ian R. Mulrenin, Anh B. Nguyen, Joshua N. Terrell, Grace Tillotson, Amber L. Beitelshees, Almut G. Winterstein, George A. Stouffer, Dominick J. Angiolillo
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 8, Pp n/a-n/a (2024)
Abstract Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor (clopidogrel, prasugrel, or ticagrelor) is indicated after percutaneous coronary intervention (PCI) to reduce the risk of atherothrombotic events. Approximately 30%
Externí odkaz:
https://doaj.org/article/7b075fa5eb614f1a8179175d280beddf
Autor:
Kayla R. Tunehag, Cameron D. Thomas, Francesco Franchi, Joseph S. Rossi, Ellen C. Keeley, R. David Anderson, Amber L. Beitelshees, Julio D. Duarte, Yan Gong, Richard A. Kerensky, Caitrin W. McDonough, Anh B. Nguyen, Luis Ortega‐Paz, Sanjay Venkatesh, Yehua Wang, Julie A. Johnson, Almut G. Winterstein, George A. Stouffer, Dominick J. Angiolillo, Larisa H. Cavallari, Craig R. Lee
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 12 (2024)
Background Cytochrome P450 2C19 (CYP2C19) intermediate and poor metabolizer patients exhibit diminished clopidogrel clinical effectiveness after percutaneous coronary intervention (PCI). However, outcome studies to date have lacked racial diversity.
Externí odkaz:
https://doaj.org/article/50016bae702e4bcbb5b7ae35deb0f244
Autor:
Amber L. Beitelshees, Cameron D. Thomas, Philip E. Empey, George A. Stouffer, Dominick J. Angiolillo, Francesco Franchi, Sony Tuteja, Nita A. Limdi, James C. Lee, Julio D. Duarte, Rolf P. Kreutz, Todd C. Skaar, James C. Coons, Jay Giri, Caitrin W. McDonough, Rachel Rowland, James M. Stevenson, Thuy Thai, Mark R. Vesely, Jacob T. Wellen, Julie A. Johnson, Almut G. Winterstein, Larisa H. Cavallari, Craig R. Lee
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 4 (2022)
Background Studies have demonstrated increased risk of major atherothrombotic events in CYP2C19 loss‐of‐function (LOF) variant carriers versus non‐carriers treated with clopidogrel after percutaneous coronary intervention (PCI). We sought to ev
Externí odkaz:
https://doaj.org/article/fdde104f3e8e43f68d0603d9571a4e08
Autor:
Nihal El Rouby, Adel Alrwisan, Taimour Langaee, Gloria Lipori, Dominick J Angiolillo, Francesco Franchi, Alberto Riva, Amanda Elsey, Julie A. Johnson, Larisa H. Cavallari, Almut G. Winterstein
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 3, Pp 473-481 (2020)
We aimed to estimate the utility of panel‐based pharmacogenetic testing of patients undergoing percutaneous coronary intervention (PCI). Utilization of Clinical Pharmacogenetic Implementation Consortium (CPIC) level A/B drugs after PCI was estimate
Externí odkaz:
https://doaj.org/article/8f025f716b6344209b03e7a5f3c108c1
Autor:
Francesco Franchi, MD, Fabiana Rollini, MD, Victor Kairouz, MD, Jose Rivas Rios, MD, Andrea Rivas, MD, Malhar Agarwal, MD, Maryuri Briceno, MD, Mustafa Wali, MD, Ahmed Nawaz, MD, Gabriel Silva, MD, Zubair Shaikh, MD, Naji Maaliki, MD, Latonya Been, AAS, Jason Piraino, DPM, Andres M. Pineda, MD, Siva Suryadevara, MD, Daniel Soffer, MD, Martin M. Zenni, MD, Lisa K. Jennings, PhD, Theodore A. Bass, MD, Dominick J. Angiolillo, MD, PhD
Publikováno v:
JACC: Basic to Translational Science, Vol 4, Iss 7, Pp 763-775 (2019)
Summary: Vorapaxar reduces thrombotic cardiovascular events at the expense of increased bleeding. However, the differential pharmacodynamic (PD) effects of vorapaxar according to diabetes mellitus (DM) status are unknown. Moreover, although withdrawa
Externí odkaz:
https://doaj.org/article/b7ea15f9ac70419180a5ce0ec8e4c853
Autor:
Francesco Franchi, Dmitry M Yaranov, Fabiana Rollini, Andrea Rivas, Jose Rivas Rios, Latonya Been, Yuma Tani, Masaaki Tokuda, Tetsuo Iida, Noriko Hayashi, Arshag D Mooradian
Publikováno v:
BMJ Open Diabetes Research & Care, Vol 9, Iss 1 (2021)
Introduction Current dietary guidelines recommend limiting sugar intake for the prevention of diabetes mellitus (DM). Reduction in sugar intake may require sugar substitutes. Among these, D-allulose is a non-calorie rare monosaccharide with 70% sweet
Externí odkaz:
https://doaj.org/article/7bfaccf322f74ea9976a9df0e0290edb
Autor:
Luis Ortega-Paz, Salvatore Giordano, Francesco Franchi, Fabiana Rollini, Charles V. Pollack, Deepak L. Bhatt, Dominick J. Angiolillo
Publikováno v:
Clinical Pharmacokinetics. 62:673-692
Publikováno v:
Trends in Cardiovascular Medicine. 33:133-138
Dual antiplatelet therapy (DAPT) represents the standard of care for patients undergoing percutaneous coronary intervention (PCI). Increasing evidence indicates that a "one-size-fits-all" approach with the use of a standard DAPT regimen for all patie
Autor:
Mattia Galli, Renzo Laborante, Luis Ortega-Paz, Francesco Franchi, Fabiana Rollini, Domenico D'Amario, Davide Capodanno, Elena Tremoli, Charles Micheal Gibson, Roxana Mehran, Dominick J. Angiolillo
Publikováno v:
Thrombosis and Haemostasis. 123:576-584
Background Phase II randomized controlled trials (RCTs) on factor(F)XI inhibitors have shown promising results but they were burdened by low statistical power for clinical outcomes. Methods We performed a systematic review and meta-analysis of RCT co
Autor:
Francesco Franchi, Luis Ortega-Paz, Fabiana Rollini, Mattia Galli, Latonya Been, Ghussan Ghanem, Awss Shalhoub, Tiffany Ossi, Andrea Rivas, Xuan Zhou, Andres M. Pineda, Siva Suryadevara, Daniel Soffer, Martin M. Zenni, Birgit Reiter, Bernd Jilma, Dominick J. Angiolillo
Publikováno v:
JACC: Cardiovascular Interventions. 16:36-46